Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 14/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191945 | 1.00 | IDH1 (1.00) | IDH1KMT2AGAAUSP2TSHR | |
| SCHEMBL15118938 | 1.00 | IDH1 (1.00) | IDH1KMT2AGAAUSP2TSHR | |
| Hydrochloric Acid SCHEMBL27209694 | 0.99 | IDH1 (0.98) | IDH1KMT2AGAAUSP2TSHR | |
| SCHEMBL30497047 | 0.99 | IDH1 (1.00) | IDH1KMT2AGAAUSP2TSHR | |
| Hydrochloric Acid SCHEMBL30191851 | 0.99 | IDH1 (0.98) | IDH1KMT2AGAAUSP2TSHR | |
| SCHEMBL15118896 | 0.99 | IDH1 (1.00) | IDH1KMT2AGAAUSP2TSHR | |
| Hydrochloric Acid SCHEMBL30191836 | 0.99 | IDH1 (0.98) | IDH1KMT2AGAAUSP2TSHR | |
| SCHEMBL15119180 | 0.92 | IDH1 (0.86) | IDH1KMT2AGAAUSP2TSHR | |
| SCHEMBL10185562 | 0.91 | IDH1 (0.85) | IDH1KMT2AUSP2TSHRMEN1 | |
| SCHEMBL15119078 | 0.90 | IDH1 (0.82) | IDH1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | UNIVERSITE DE LAUSANNE (CH) | 2024-05-02 | — | — | US | claimed |
| EP-4114378-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | Université de Lausanne (CH) | 2023-01-11 | — | — | EP | claimed |
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4598539-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12168005-B2 | Methods for treating wild type isocitrate dehydrogenase 1 cancers | UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024229332-A1 | ANTI-CANCER TREATMENTS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-118613480-A | Polycyclic IRAK and FLT3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024163764-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4377315-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | UNIVERSITE DE LAUSANNE (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2024076614-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230121197-A1 | ANTIBODIES SPECIFICALLY BINDING THE CARBOXYMETHYLATED CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE 2A | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2023-04-20 | — | — | US | disclosed |
| WO-2023009833-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4114378-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | Université de Lausanne (CH) | 2023-01-11 | — | — | EP | disclosed |
| EP-4093776-A1 | ANTIBODIES SPECIFICALLY BINDING THE CARBOXYMETHYLATED CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE 2A | Medizinische Universität Wien (AT) | 2022-11-30 | — | — | EP | disclosed |
| EP-4041922-A1 | METHODS FOR TREATING WILD TYPE ISOCITRATE DEHYDROGENASE 1 CANCERS | University Hospitals Cleveland Medical Center (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168005-B2 | Methods for treating wild type isocitrate dehydrogenase 1 cancers | IDH1, IDH2, IDH3A | IDH1 1/4885KMT2A 257/4885GAA 99/4885 |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | CYFIP1, GABARAPL1, GABRR1 | IDH1 3601/4885KMT2A 3834/4885GAA 791/4885 |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | IDH1 141/4885KMT2A 270/4885GAA 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.